What Iscaffpharma offers

Iscaffpharma provides a cost-effective platform to improve success rate in clinical development of treatments for aggressive and orphan cancer

Products & Services

Development support

We offer support with cancer drug development using 3D scaffolds. Our technology identifies targets associated to tumour aggressiveness and offers screening of NCEs (new chemical entities) on gene expression and other factors.

Development services are focused on solid cancer in:
– Breast
– Colon
– Ovarian
– Orphan

Iscaffpharma is currently researching additional cancer forms

3D printed scaffolds & Licensing of Technologies

The 3D printed scaffolds are available to partners wishing to conduct there own development either by

– Own printing of scaffold with Iscaffpharmas patented recipe
– Printed and distributed by Iscaffpharma

In a restricted number of partners Iscaffpharma will license the scaffold technology.

Diagnostics

Iscaffpharma offers precision diagnostics enabling personalised treatment. We are also offering liquid biopsy as an additional diagnostic tool

Precision diagnostics
Personalized treatment
Liquid biopsy

Advantages in drug development

  • Identifying new targets, validation of targets
  • Predicting NCEs effect on aggressive and recurrent cancer (Indicating effect on phase 3 endpoints)
  • In vivo like model. Mimics true human environment
  • Cost effective and improves relevance of preclinical screening
    • Reduced need for animal testing
    • 3D model enables large scale testing
  • Increases success rate of cancer projects

Improving drug development

Drug discovery and development is known to be a time and cost consuming effort. Iscaffpharmas patented scaffold technology will:

  • Improve target and lead generation
  • Improve quality for drug discovery and preclinical phase
  • Reduce use of animal xenographs

Increases success rate in clinical trials due to preclinical testing in human, in-vivo, like setting. The predictive platform technology is applicable on any solid tumours

timeline

Source: http://biomedicalresearch.alliedacademies.com/events-list/drug-discovery-and-development-2018

Orphan cancer

Iscaffpharmas precision medicine offers opportunities to conduct research in Orphan cancer. We can offer testing in in-vivo like settings for targets and substances where no other methods are available.

Partners, Collaborators and Investors

Iscaffpharma is part of UDI3 challenge driven innovation supported by Vinnova. Our partners are:

vgregunivhosp_o-01
1593648_guv.rgb_
skanes-universitetssjukhus-logga
tataa_logo_liggande_a4_cmyk_300dpi
1514062_sacancercenter-kopia
cellprotect-pharmaceuticals
respiratorius-logo03-black-200712
logueng_cen2r
rise_logo_rgb_dr44mov
oblique
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search